COMPANY PROFILE

Apnimed

Explore full profile

Clinical-stage company advancing oral medicines to treat Obstructive Sleep Apnea and related disorders

Cambridge, United StatesFounded 2017Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2026

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Apnimed

Apnimed, based in Cambridge, MA, is a clinical-stage pharmaceutical company dedicated to developing novel oral therapies for obstructive sleep apnea (OSA) and related disorders. The company focuses on addressing the neurological aspects of OSA, a condition where the upper airway closes during sleep, leading to reduced blood oxygen levels and disrupted sleep. Apnimed's lead candidate, AD109, aims to be the first disease-modifying oral therapeutic for OSA, representing a significant shift from current treatments that often involve mechanical devices or surgery. The company operates in the biotechnology sector, targeting patients suffering from sleep apnea and symptomatic snoring. Apnimed's business model revolves around the research, development, and eventual commercialization of its therapeutic candidates. Revenue generation is expected through the sale of these oral medications once they receive regulatory approval. The company has garnered recognition for its innovative approach, including being named one of the most promising biotechnology companies by Fierce Biotech.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Cambridge, United States
Employees: 87
Open positions: 10
Dealroom signal: 75.1/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Mental Health, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBTDebt	Apr 2026	$50M	—	HealthCare Royalty	↗
SERIES COther financing	Jan 2023	$80M	$319M	Tao Capital Partners · Sectoral Asset Management · Columbia Seligman Investments · Alpha Wave Ventures	↗

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Apnimed website traffic

Latest recorded traffic for Apnimed is 74K monthly website visits, up 174.1% over the last three months. Apnimed's team grew 6.1% over the past year.

Latest monthly visits74K 3-month web change+174.1% 1-year team growth+6.1%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Sr. Director of Human Resources OperationsSan Diego, CA · Human Resources · Sep 5, 2026 Director, Medical OperationsCambridge, MA · Other · Aug 28, 2026 Associate Director, Publications & Medical CommunicationsCambridge, MA · Marketing & Communication · Aug 28, 2026 Value Outcomes Liaison/Sr. Value Outcomes LiaisonCambridge, MA · Accounting · Aug 15, 2026 Director, Consumer Strategy and ExperienceCambridge, MA · Marketing & Communication · Aug 12, 2026 Manager, Revenue AccountingCambridge, MA · Accounting · Aug 9, 2026 Assistant ControllerCambridge, MA · Other · Aug 6, 2026

7 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTranscend TherapeuticsDeveloping the next generation of psychoactive compounds for neuropsychiatry focused on patient access	New York City, United States	Acquired	31	$42M	$700M
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
ANAlto NeuroscienceClinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform	Los Altos, United States	Operational
EBEywa BiotechBiosynthetic psychedelic APIs for mental health treatments	Montevideo, Uruguay	Operational
SBSyndeio BiosciencesDeveloping rapid-acting therapies to enhance synaptic health and treat CNS disorders through novel synapse pharmacology	Indianapolis, United States	Operational
BBBright Minds BiosciencesBiotechnology company creating the next generation of psychedelics to treat mental health and other CNS disorders	New York City, United States	Operational
GPGilgamesh PharmaceuticalsProvides medicines for psychedelic, novel psychotropic drugs, depression, anxiety, and stress-related disorders	New York City, United States	Operational
AKAkiliDelivering the first-and-only prescription treatment delivered through a video game	Boston, United States	Acquired